Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(34 sites)

United States

The Kirklin Clinic of UAB Hospital, Birmingham, Alabama

City of Hope Comprehensive Cancer Center, Duarte, California

University of California Irvine, Irvine, California

UCSD Moores Cancer Center, La Jolla, California

USC/Norris Comprehensive Cancer Center, Los Angeles, California